Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept for non-infectious lung complications after allogeneic stem cell transplantation
jRCTs041180010Completed
- Start
- Jun 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of etanercept in pulmonary complications after allogeneic hematopoietic stem cell transplantation (PC-alloHSCT). Primary endpoint: Complete response rate at day 28. Started Jun 2018; status: completed.
02
Drugs
etanercept
03
Conditions
pulmonary complications after allogeneic hematopoietic stem cell transplantation (PC-alloHSCT)
Beyond the preview
Go deeper on jRCTs041180010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180010.